[Drugs in the Developmental Stage (Psychotropics)].
May 1, 2023 DOI: 10.11477/mf.1416202356 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review |
|---|---|
| Topics | Psilocybin |
| Keywords | Drug development Neuropsychopharmacology |
| Citations | 1 |
| Key findings | Drugs with novel mechanisms of action are being investigated, representing a new dawn in clinical psychopharmacology despite industry withdrawals from CNS drug development. |
Abstract
In recent years, it is common for a single drug to be developed for multiple diseases almost simultaneously, e.g., pimavanserin and psilocybin. Although there was gloomy news for the field of neuropsychopharmacology, such as withdrawal of the world's leading mega-pharmaceutical companies from the development of CNS drugs, drugs based on novel mechanisms of action have been investigated. This is a new dawn in the field of clinical psychopharmacology.
Comparable studies
Other narrative reviews on psilocybin, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Classic psychedelics: An integrative review of epidemiology, therapeutics, mystical experience, and brain network function. General population | 2019 | Integrative review | |
| The pharmacology of psilocybin | 2002 | Review | |
| Serotonin research: contributions to understanding psychoses | 2008 | Review | |
| Psychedelics, Meditation, and Self-Consciousness | 2018 | Review | |
| The abuse potential of medical psilocybin according to the 8 factors of the Controlled Substances Act | 2018 | Review |